Published in Mol Cancer Res on September 01, 2006
Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis. Breast Cancer Res (2012) 1.65
Honokiol, a multifunctional antiangiogenic and antitumor agent. Antioxid Redox Signal (2009) 1.53
Honokiol suppresses survival signals mediated by Ras-dependent phospholipase D activity in human cancer cells. Clin Cancer Res (2008) 1.43
Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors. Clin Cancer Res (2010) 1.25
Honokiol is a potent scavenger of superoxide and peroxyl radicals. Biochem Pharmacol (2008) 1.17
Honokiol in combination with radiation targets notch signaling to inhibit colon cancer stem cells. Mol Cancer Ther (2012) 1.13
Improved therapeutic effectiveness by combining liposomal honokiol with cisplatin in lung cancer model. BMC Cancer (2008) 0.98
Honokiol inhibits epithelial-mesenchymal transition in breast cancer cells by targeting signal transducer and activator of transcription 3/Zeb1/E-cadherin axis. Mol Oncol (2014) 0.96
The natural product honokiol preferentially inhibits cellular FLICE-inhibitory protein and augments death receptor-induced apoptosis. Mol Cancer Ther (2008) 0.94
Identifying new small molecule anti-invasive compounds for glioma treatment. Cell Cycle (2013) 0.94
Honokiol activates reactive oxygen species-mediated cytoprotective autophagy in human prostate cancer cells. Prostate (2014) 0.93
Leoligin, the major lignan from Edelweiss, inhibits intimal hyperplasia of venous bypass grafts. Cardiovasc Res (2009) 0.93
Honokiol enhances paclitaxel efficacy in multi-drug resistant human cancer model through the induction of apoptosis. PLoS One (2014) 0.88
Different redox states in malignant and nonmalignant esophageal epithelial cells and differential cytotoxic responses to bile acid and honokiol. Antioxid Redox Signal (2009) 0.86
Use of chinese herb medicine in cancer patients: a survey in southwestern china. Evid Based Complement Alternat Med (2012) 0.85
In vitro growth inhibition of human cancer cells by novel honokiol analogs. Bioorg Med Chem (2012) 0.81
Honokiol suppresses TNF-α-induced neutrophil adhesion on cerebral endothelial cells by disrupting polyubiquitination and degradation of IκBα. Sci Rep (2016) 0.81
Honokiol inhibits androgen receptor activity in prostate cancer cells. Prostate (2013) 0.80
Synergistic antitumor effects of liposomal honokiol combined with cisplatin in colon cancer models. Oncol Lett (2011) 0.78
Preparation and characterization of honokiol nanoparticles. J Mater Sci Mater Med (2008) 0.78
Honokiol ameliorates endothelial dysfunction through suppression of PTX3 expression, a key mediator of IKK/IκB/NF-κB, in atherosclerotic cell model. Exp Mol Med (2015) 0.78
Translating cyclooxygenase signaling in patch heterozygote mice into a randomized clinical trial in basal cell carcinoma. Cancer Prev Res (Phila) (2010) 0.76
Honokiol Induces Apoptosis, G1 Arrest, and Autophagy in KRAS Mutant Lung Cancer Cells. Front Pharmacol (2017) 0.75
Non-toxic dose of liposomal honokiol suppresses metastasis of hepatocellular carcinoma through destabilizing EGFR and inhibiting the downstream pathways. Oncotarget (2016) 0.75
Antineoplastic Effects of Honokiol on Melanoma. Biomed Res Int (2017) 0.75
Honokiol as a Radiosensitizing Agent for Colorectal cancers. Curr Colorectal Cancer Rep (2013) 0.75
c-Myc is a novel target of cell cycle arrest by honokiol in prostate cancer cells. Cell Cycle (2016) 0.75
Honokiol, a Lignan Biphenol Derived from the Magnolia Tree, Inhibits Dengue Virus Type 2 Infection. Viruses (2015) 0.75
Magnolol reduces bleomycin-induced rodent lung fibrosis. Int J Clin Exp Med (2015) 0.75
Honokiol Alleviates Hypertrophic Scar by Targeting Transforming Growth Factor-β/Smad2/3 Signaling Pathway. Front Pharmacol (2017) 0.75
Modulating testosterone pathway: a new strategy to tackle male skin aging? Clin Interv Aging (2012) 0.75
The new 4-O-methylhonokiol analog GS12021 inhibits inflammation and macrophage chemotaxis: role of AMP-activated protein kinase α activation. PLoS One (2015) 0.75
Biological activity and toxicity of the Chinese herb Magnolia officinalis Rehder & E. Wilson (Houpo) and its constituents. J Zhejiang Univ Sci B (2017) 0.75
Honokiol inhibits bladder cancer cell invasion through repressing SRC-3 expression and epithelial-mesenchymal transition. Oncol Lett (2017) 0.75
Bioavailability of curcumin: problems and promises. Mol Pharm (2007) 8.72
Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med (2010) 7.31
Inflammation and cancer: how hot is the link? Biochem Pharmacol (2006) 5.17
Curcumin as "Curecumin": from kitchen to clinic. Biochem Pharmacol (2007) 5.13
Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res (2004) 4.69
Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol (2006) 4.69
Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res (2008) 4.29
Nuclear factor-kappaB: its role in health and disease. J Mol Med (Berl) (2004) 4.01
Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett (2008) 3.61
Cancer is a preventable disease that requires major lifestyle changes. Pharm Res (2008) 3.28
Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship?. Ann N Y Acad Sci (2009) 3.27
Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci (2008) 3.16
Curcumin and cancer: an "old-age" disease with an "age-old" solution. Cancer Lett (2008) 3.14
Peroxisome proliferation-associated control of reactive oxygen species sets melanocortin tone and feeding in diet-induced obesity. Nat Med (2011) 3.09
Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res (2009) 2.98
Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochem Pharmacol (2008) 2.95
Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? AAPS J (2009) 2.89
Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways. Mol Pharmacol (2007) 2.70
Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation. Mol Pharmacol (2005) 2.62
Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev (2010) 2.57
Inhibiting NF-κB activation by small molecules as a therapeutic strategy. Biochim Biophys Acta (2010) 2.55
Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res (2005) 2.46
Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann N Y Acad Sci (2006) 2.44
Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol (2003) 2.44
Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo. J Biol Chem (2003) 2.44
"Spicing up" of the immune system by curcumin. J Clin Immunol (2007) 2.43
Curcumin: getting back to the roots. Ann N Y Acad Sci (2005) 2.42
Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J (2012) 2.42
Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochem Pharmacol (2002) 2.27
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res (2006) 2.24
Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem Pharmacol (2003) 2.22
Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. J Clin Invest (2007) 2.22
Reactive oxygen intermediates in TNF signaling. Mol Immunol (2002) 2.20
Nuclear factor-kappaB activation: from bench to bedside. Exp Biol Med (Maywood) (2008) 2.19
Mitogen-actived protein kinase activation is an early event in melanoma progression. Clin Cancer Res (2002) 2.18
Targeted therapy of oral hairy leukoplakia with gentian violet. J Am Acad Dermatol (2008) 2.17
Retracted Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharmacol (2009) 2.12
Resveratrol: a multitargeted agent for age-associated chronic diseases. Cell Cycle (2008) 2.10
Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta (2010) 2.08
Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid Redox Signal (2012) 2.05
Hydrogen peroxide activates NF-kappa B through tyrosine phosphorylation of I kappa B alpha and serine phosphorylation of p65: evidence for the involvement of I kappa B alpha kinase and Syk protein-tyrosine kinase. J Biol Chem (2003) 2.05
Transcription factor NF-kappaB: a sensor for smoke and stress signals. Ann N Y Acad Sci (2005) 2.05
NF-kappaB and cancer: how intimate is this relationship. Mol Cell Biochem (2009) 2.03
Role of curcumin in cancer therapy. Curr Probl Cancer (2007) 2.00
Cancer prevention with natural compounds. Semin Oncol (2010) 1.98
Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res (2007) 1.98
Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem Pharmacol (2005) 1.94
A synthetic triterpenoid, CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cells. Clin Cancer Res (2006) 1.92
TNF: a master switch for inflammation to cancer. Front Biosci (2008) 1.91
Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem (2003) 1.91
Anticancer potential of silymarin: from bench to bed side. Anticancer Res (2007) 1.91
Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res (2004) 1.90
Role of chemopreventive agents in cancer therapy. Cancer Lett (2004) 1.88
Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. Clin Cancer Res (2008) 1.88
The molecular inflammatory process in aging. Antioxid Redox Signal (2006) 1.86
Necrosis and glioblastoma: a friend or a foe? A review and a hypothesis. Neurosurgery (2002) 1.83
Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway. Cancer Res (2006) 1.82
A key role for NOX4 in epithelial cell death during development of lung fibrosis. Antioxid Redox Signal (2011) 1.79
Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome c release: its suppression by ectopic expression of Bcl-2 and Bcl-xl. Carcinogenesis (2002) 1.79
Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res (2002) 1.78
Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism. Carcinogenesis (2007) 1.78
Thymoquinone: potential cure for inflammatory disorders and cancer. Biochem Pharmacol (2011) 1.76
Retracted Cyclodextrin-complexed curcumin exhibits anti-inflammatory and antiproliferative activities superior to those of curcumin through higher cellular uptake. Biochem Pharmacol (2010) 1.72
Cancer drug discovery by repurposing: teaching new tricks to old dogs. Trends Pharmacol Sci (2013) 1.72
Pharmacologic blockade of angiopoietin-2 is efficacious against model hemangiomas in mice. J Invest Dermatol (2006) 1.72
Discovery of curcumin, a component of golden spice, and its miraculous biological activities. Clin Exp Pharmacol Physiol (2012) 1.72
Fulvene-5 potently inhibits NADPH oxidase 4 and blocks the growth of endothelial tumors in mice. J Clin Invest (2009) 1.68
Genetic deletion of glycogen synthase kinase-3beta abrogates activation of IkappaBalpha kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis induced by tumor necrosis factor. J Biol Chem (2004) 1.66
Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis. Breast Cancer Res (2012) 1.65
Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling. Cancer Res (2008) 1.63
Cigarette smoke condensate activates nuclear transcription factor-kappaB through phosphorylation and degradation of IkappaB(alpha): correlation with induction of cyclooxygenase-2. Carcinogenesis (2002) 1.63